Published in
Oxford University Press (OUP), Annals of Oncology, (29), p. viii304, 2018
DOI: 10.1093/annonc/mdy283.073
Links
Tools
Pembrolizumab for high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG): Phase II KEYNOTE-057 trial
Journal article published in 2018 by
R. de Wit,
G. S. Kulkarni,
E. Uchio,
E. A. Singer,
L. Krieger,
P. Grivas,
H. K. Seo,
L. Mourey,
A. Kamat,
H. Nishiyama,
E. Kapadia,
K. Nam,
T. Frenkl,
D. Bajorin,
Arjun Balar 
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 